<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24346900</article-id>
      <article-id pub-id-type="pmc">3875977</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20131731</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Primary cutaneous anaplastic large-cell lymphoma - Case report<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
        <trans-title-group xml:lang="pt">
          <trans-title>Linfoma cut&#xE2;neo prim&#xE1;rio de grandes c&#xE9;lulas anapl&#xE1;sicas - relato de
caso</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Luciana Silveira Rabello</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Nobrega</surname>
            <given-names>Madeleyne Palhano</given-names>
          </name>
          <xref ref-type="aff" rid="aff02">2</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Monteiro</surname>
            <given-names>Maira Gomes</given-names>
          </name>
          <xref ref-type="aff" rid="aff03">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Almeida</surname>
            <given-names>Wagner Leite</given-names>
          </name>
          <xref ref-type="aff" rid="aff04">4</xref>
        </contrib>
      </contrib-group>
      <aff id="aff01"><label>1</label> MD, Dermatologist - Master's degree in Public Health - Professor at the
Federal University of Campina Grande (UFCG) - Campina Grande (PB), Brazil.</aff>
      <aff id="aff02"><label>2</label> MD, Endocrinologist at the Center for Endocrinology and Metabolism -
Campina Grande (PB), Brazil.</aff>
      <aff id="aff03"><label>3</label> MD, Immunologist at the University Hospital Alcides Carneiro - Federal
University of Campina Grande (HUAC-UFCG) - Campina Grande (PB), Brazil.</aff>
      <aff id="aff04"><label>4</label> MD, Pathologist at the Campinense Unit of Diagnosis - Campina Grande
(PB), Brazil.</aff>
      <author-notes>
        <corresp id="c01"><bold>Mailing address:</bold> Madeleyne Palhano Nobrega, 840 Arquilino de Souza
Guimaraes St., 58402-030 - Campina Grande - PB, Brazil. E-mail:
<email>madeleynepalhano@ig.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="ppub">
        <season>Nov-Dec</season>
        <year>2013</year>
      </pub-date>
      <volume>88</volume>
      <issue>6 Suppl 1</issue>
      <fpage>132</fpage>
      <lpage>135</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>2</month>
          <year>2012</year>
        </date>
        <date date-type="accepted">
          <day>12</day>
          <month>11</month>
          <year>2012</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2013 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Primary cutaneous anaplastic large-cell lymphoma is part of the spectrum of CD30+
lymphoproliferative cutaneous processes, characterized by single or multifocal
nodules that ulcerate, are autoregressive and recurrent. Extracutaneous dissemination
may occur, especially to regional lymph nodes. Histology shows a diffuse,
non-epidermotropic infiltrate , anaplastic large lymphoid cells of
immunohistochemistry CD30+, CD4+, EMA-/+, ALK-, CD15- and TIA1-/+. Prognosis is good
and does not depend on lymphatic invasion. Radiotherapy, removal of the lesion and/or
low-dose methotrexate are the treatments of choice. The present study reports the
case of a 57-year-old-woman presenting Primary cutaneous anaplastic large-cell
lymphoma with multifocal lesions. The pacient evolved with pulmonary involvement 7
years later. She showed a good response to the treatment with low-dose methotrexate
prescribed weekly.</p>
      </abstract>
      <trans-abstract xml:lang="pt">
        <p>Linfoma cut&#xE2;neo prim&#xE1;rio de grandes c&#xE9;lulas T anapl&#xE1;sicas faz parte do espectro de
processos linfoproliferativos cut&#xE2;neos CD30+ e caracteriza-se por n&#xF3;dulos &#xFA;nicos ou
multifocais, ulcerados, autorregressivos e recidivantes. Pode haver dissemina&#xE7;&#xE3;o
extracut&#xE2;nea, principalmente para linfonodos regionais. O histol&#xF3;gico mostra
infiltrado difuso, n&#xE3;o-epidermotr&#xF3;pico, grandes c&#xE9;lulas linf&#xF3;ides anapl&#xE1;sicas de
imunohistoqu&#xED;mica CD30+, CD4+, EMA-/+, ALK-, CD15- e TIA1-/+. O progn&#xF3;stico &#xE9; bom e
independe da invas&#xE3;o ganglionar. Radioterapia, retirada da les&#xE3;o e/ou metotrexato em
baixas doses s&#xE3;o os tratamentos de escolha. Este estudo relata o caso de uma mulher,
57 anos, com Linfoma cut&#xE2;neo prim&#xE1;rio de grandes c&#xE9;lulas T com les&#xF5;es multifocais e
que, ap&#xF3;s 7 anos, evoluiu com acometimento pulmonar. Apresentou boa resposta ao
tratamento com metotrexato em baixas doses semanais.</p>
      </trans-abstract>
      <kwd-group>
        <kwd>Lymphoma, large-cell, anaplastic</kwd>
        <kwd>Lymphoma, primary cutaneous anaplastic large cell</kwd>
        <kwd>Lymphoma, T-cell</kwd>
        <kwd>Lymphoma, T-cell, cutaneous</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>INTRODUCTION</title>
      <p>The primary cutaneous anaplastic large cell lymphoma (PCALCL) is a non-Hodgkin lymphoma
(NHL) of cutaneous T-cell presentation, without systemic involvement at the time of the
diagnosis and in the next six months. It has been well-established that PCALCL express
the CD30 antigen in more than 75% of their tumor cells.1 The incidence of PCALCL among
other types of peripheral T-cell NHL is 1.7%. It reaches an overall peak in the sixth
decade of life and an average of 50% of cases are diagnosed in patients aged
61.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>Most patients present with solitary or localized nodules, papules or plaques. However,
up to 20% of patients may have multiple lesions. Ulceration may be present or not. The
lesions usually occur on the trunk, face, extremities and buttocks and are usually
asymptomatic. <sup><xref ref-type="bibr" rid="r03">3</xref></sup> Histologically, these
lesions show a diffuse infiltrate composed of large sized T lymphocytes with
characteristic morphology of anaplastic cells with round, oval or irregular nuclei,
prominent eosinophilic nucleoli and abundant cytoplasm; normally, they do not present
with epidermotropism.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r03">3</xref></sup> The immunophenotype consists of CD4+, CD30+, CLA+,
EMA-/+, TIA1-/+, and CD15-ALK-3.</p>
      <p>The diagnosis of cutaneous lymphomas is difficult and often delayed, because of the
large number of differential diagnoses involving the entire spectrum of primary or
secondary CD30+ cutaneous processes.</p>
      <p>The main differential diagnoses include lymphomatoid papulosis (LP) and systemic
anaplastic large cell lymphoma with cutaneous involvement.<sup><xref ref-type="bibr" rid="r04">4</xref></sup>
</p>
      <p>To distinguish PCALCL and LP, longitudinal observation is often necessary as the
histopathological differentiation between the two conditions is difficult. LP lesions
are smaller (&lt;3 cm). Although more diffuse, they are self-limited and do not progress
with time.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r05">5</xref></sup>
</p>
      <p>Regarding systemic lymphoma, it is more common in young men, under 35 years old,
presenting with disease in stage III or IV with lymphadenopathy, B symptoms and a short
and progressive course , besides presenting translocation t (2.5) expressing
ALK+.<sup><xref ref-type="bibr" rid="r03">3</xref>,<xref ref-type="bibr" rid="r06">6</xref></sup>
</p>
      <p>It is an indolent neoplasm with good prognosis and five-year survival rate between 76%
and 96%.<sup><xref ref-type="bibr" rid="r07">7</xref></sup> Cutaneous recurrences are
frequent (39%) and extra-cutaneous dissemination occurs in about 13% of cases, mainly to
regional lymph nodes.<sup><xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>Radiation therapy, removal of the lesion and/or low-dose methotrexate are the preferred
treatments among patients with localized lesions.<sup><xref ref-type="bibr" rid="r03">3</xref></sup> Rapidly progressive or extracutaneous disease should be treated
with systemic polychemotherapy.<sup><xref ref-type="bibr" rid="r02">2</xref></sup>
</p>
      <p>In this paper, a case of primary cutaneous CD30+ anaplastic large T-cell lymphoma is
reported for its exuberance and rarity.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>A woman, aged 57, female, from Campina Grande-PB, has had skin lesions since 2001. The
lesions began as eczema located in upper and lower limbs that have evolved to a
widespread scaly and quite pruritic rash with papules and nodules which ulcerated and
spontaneously regressed, leaving permanent hypochromic stains (<xref ref-type="fig" rid="f01">Figures 1</xref> and <xref ref-type="fig" rid="f02">2</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Widespread scaly eruption with ulcerated nodules and scarring hypochromic
spots</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0132-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Lesions on scalp</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0132-g02"/>
      </fig>
      <p>She did outpatient treatment with a specialist since the onset of disease, but she only
received a definitive diagnosis in 2007 (after six years of evolution). Until the
diagnosis, she had been given oral antihistamines and topical steroids, without
improvement. She also needed hospitalizations for secondary infections.</p>
      <p>She underwent three skin biopsies (in 2004, 2006 and 2007); the first two were not
conclusive.</p>
      <p>The lesion biopsy performed in 2007 showed infiltration of atypical lymphoid cells of
medium and large sizes in the superficial and reticular dermis and in the subcutaneous
tissue with significant eosinophilia (<xref ref-type="fig" rid="f03">Figure 3</xref>)
suggesting the creation of a immunohistochemical panel for cancer that was positive for
CD30 , CD3 and CD15 markers and negative for Ki67 and ALK.</p>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Infiltration of medium and large atypical lymphoid cells in the superficial and
reticular dermis and in the subcutaneous tissue, with significant eosinophilia</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0132-g03"/>
      </fig>
      <p>As for the diagnosis, tomography of the chest showed several nodules scattered
throughout the parenchyma of both lungs (<xref ref-type="fig" rid="f04">Figure
4</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Chest CT scan showing parenchymal nodule in the left hemithorax</p>
        </caption>
        <graphic xlink:href="abd-88-06-s1-0132-g04"/>
      </fig>
      <p>Treatment was initiated with methotrexate in weekly doses and achieved good clinical
response.</p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>A case of CD30+ PCALCL in a 57-year-old woman was reported. In the literature, this type
of lymphoma affects more frequently males than females with a ratio of
1.5-2:1.<sup><xref ref-type="bibr" rid="r01">1</xref>,<xref ref-type="bibr" rid="r02">2</xref></sup> Regarding the age group, it affects more adults in the
sixth decade of life<sup><xref ref-type="bibr" rid="r04">4</xref></sup> and the
aforementioned patient is close to this age group.</p>
      <p>Most patients with PCALCL present with localized lesions and up to 20% of patients may
have multiple lesions.<sup><xref ref-type="bibr" rid="r02">2</xref></sup> In this case,
the lesion was characterized by a scaly and quite pruritic rash with multiple papular
and nodular ulcerated lesions, disseminated throughout the body. The lesions improved
spontaneously as well as regressed, which is consistent with recent literature.</p>
      <p>The most common form of systemic involvement is regional lymph nodes, but the patient
had an atypical systemic involvement on lung, after seven years of evolution.<sup><xref ref-type="bibr" rid="r06">6</xref>,<xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>Considering the size of the lesions presented and their progression over the years, the
differential diagnosis between LP and PCALCL favored lymphoma.</p>
      <p>Systemic lymphoma was ruled out as the patient had no other complaints, except those
related to skin lesions; no systemic involvement was revealed on the onset of disease
and until seven years later (CT and myelogram normal); ALK+ was not expressed; and a
good prognosis was shown.</p>
      <p>The treatment with methotrexate in weekly doses proved effective, as shown in
literature, in which with a 15-20 mg weekly, response occurs in approximately 87% of
patients.<sup><xref ref-type="bibr" rid="r08">8</xref></sup>
</p>
      <p>This case report shows the importance of defining the diagnosis to individualize
treatment, avoiding aggressive conduct for treating a disease with good prognosis,
despite the exuberance of clinical manifestation. Regardless of good prognosis, it is
necessary to closely monitor these patients because of the potential risk of
dissemination or extracutaneous spread, besides recurrence of the disease or even
development of other malignancies, such as mycosis fungoides, Hodgkin or non-Hodgkin
lymphomas.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <p>* Work performed at the University Hospital Alcides Carneiro - Federal University of
Campina Grande (HUAC-UFCG) - Campina Grande (PB), Brazil.</p>
      </fn>
      <fn id="fn02" fn-type="conflict">
        <p>Conflict of interest: None</p>
      </fn>
      <fn id="fn03" fn-type="financial-disclosure">
        <p>Financial funding: None</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES </title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kempf</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pfaltz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Vermeer</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Cozzio</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ortiz-Romero</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Bagot</surname>
              <given-names>M</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>EORTC, ISCL, and USCLC consensus recommendations for the treatment of
primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid
papulosis and primary cutaneous anaplastic large-cell lymphoma</article-title>
          <source>Blood</source>
          <year>2011</year>
          <volume>118</volume>
          <fpage>4024</fpage>
          <lpage>4035</lpage>
          <pub-id pub-id-type="pmid">21841159</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamantidis</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Papadopoulos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaiafa</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Ntaios</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Karayannopoulou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kostopoulos</surname>
              <given-names>I</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title> Differential diagnosis and treatment of primary, cutaneous,
anaplastic large cell lymphoma: not always an easy task </article-title>
          <source>Int J Hematol</source>
          <year>2009</year>
          <volume>90</volume>
          <fpage>226</fpage>
          <lpage>229</lpage>
          <pub-id pub-id-type="pmid">19548068</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diamantidis</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Myrou</surname>
              <given-names>AD</given-names>
            </name>
          </person-group>
          <article-title>Perils and Pitfalls Regarding Differential Diagnosis and Treatment of
Primary Cutaneous Anaplastic Large-Cell Lymphoma</article-title>
          <source>ScientificWorldJournal</source>
          <year>2011</year>
          <volume>11</volume>
          <fpage>1048</fpage>
          <lpage>1055</lpage>
          <pub-id pub-id-type="pmid">21552770</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kadin</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Current management of primary cutaneous CD30+ T-cell
lymphoproliferative disorders</article-title>
          <source>Oncology (Williston Park)</source>
          <year>2009</year>
          <volume>23</volume>
          <fpage>1158</fpage>
          <lpage>1164</lpage>
          <pub-id pub-id-type="pmid">20043465</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duvic</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Improved understanding of peripheral T-cell lymphomas</article-title>
          <source>Oncology (Williston Park)</source>
          <year>2010</year>
          <volume>24</volume>
          <fpage>587</fpage>
          <lpage>593</lpage>
          <page-range>587,592-3</page-range>
          <pub-id pub-id-type="pmid">20669795</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Benner</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Willemze</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Applicability and prognostic value of the new TNM classification
system in 135 patients with primary cutaneous anaplastic large cell
lymphoma</article-title>
          <source>Arch Dermatol</source>
          <year>2009</year>
          <volume>145</volume>
          <fpage>1399</fpage>
          <lpage>1404</lpage>
          <pub-id pub-id-type="pmid">20026848</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Hoppe</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Kohler</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Harvell</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Reddy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
          </person-group>
          <article-title>CD30+ cutaneous lymphoproliferative disorders: the Stanford experience
in lymphomatoid papulosis and primary cutaneous anaplastic large cell
lymphoma</article-title>
          <source>J Am Acad Dermatol</source>
          <year>2003</year>
          <volume>49</volume>
          <fpage>1049</fpage>
          <lpage>1058</lpage>
          <pub-id pub-id-type="pmid">14639383</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bekkenk</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Geelen</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>van Voorst Vader</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Heule</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Geerts</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>van Vloten</surname>
              <given-names>WA</given-names>
            </name>
            <etal>et al</etal>
          </person-group>
          <article-title>Primary and secondary cutaneous CD30+ lymphoproliferative disorders: a
report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of
219 patients and guidelines for diagnosis and treatment</article-title>
          <source>Blood</source>
          <year>2000</year>
          <volume>95</volume>
          <fpage>3653</fpage>
          <lpage>3661</lpage>
          <pub-id pub-id-type="pmid">10845893</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
